{"database": "openregs", "table": "docket_stats", "rows": [[62890, "FDA-2026-P-2353", "FDA", "Requests that the FDA declare that the drug products Progesterone Tablets, 150 mg and 300 mg, are suitable for consideration in an Abbreviated New Drug Application.", "Nonrulemaking", 0, 9, null, null, "2026-03-06T05:00:00Z", "2026-08-28T04:00:00Z"]], "columns": ["rowid", "id", "agency_id", "title", "docket_type", "comment_count", "document_count", "earliest_comment", "latest_comment", "earliest_document", "latest_document"], "primary_keys": ["rowid"], "primary_key_values": ["62890"], "units": {}, "query_ms": 0.28959685005247593, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}